Q-omics provides the consensus-scored CASC16 profile across patient tissues and cancer cell-line models. CASC16 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, CASC16 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, CASC16 RNA expression shows 10,541 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, COAD, and TGCT as cancer lineages where CASC16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CASC16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CASC16 survival associations across molecular data types. CASC16 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CASC16 RNA expression–survival associations across cancer types. High CASC16 expression shows unfavorable associations in DLBC and STAD, but favorable associations in BLCA, ACC, KIRP and PAAD. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify DLBC as the clearest survival context for CASC16 RNA expression.
This table summarizes CASC16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CASC16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CASC16 shows lower tumor expression in COAD and KIRC and higher tumor expression in LUAD, KICH, BRCA and LIHC. The COAD box plot shows higher CASC16 RNA expression in normal versus tumor tissue (log2 FC = −0.550, t-test p < 0.001).
This table shows molecular features associated with CASC16 in patient tissues and cancer cell lines. In patient samples, CASC16 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
